Zoledronic acid has several advantages over other bisphosphonates. In addition to having broader clinical utility, zoledronic acid can safely be infused over 15 minutes rather than the 2 hours ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

Please provide your email address to receive an email when new articles are posted on . Published results showed integration of fracture liaison and orthopedic services, as well as inpatient ...

Novartis Pharmaceuticals Corp. in East Hanover, an affiliate of Novartis AG, says it has received approval from the Food and Drug Administration for zoledronic acid (Reclast) injection as a ...

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis Study of over 7,700 women published today shows reduction of 70 percent in spine fractures and 41 ...

U.S. FDA Approves Novartis Corporation's Reclast, the First and Only Single-Dose Treatment Regimen for Paget's Disease of the Bone NEW YORK, April 17 -- The U.S. Food and Drug Administration (FDA) has ...

Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years of ...

In general, IV bisphosphonates are very well tolerated, and patients rarely require dose modification. In the comparative phase 3 trial of zoledronic acid and pamidronate in patients with breast ...